NASDAQ$SRPT
Sarepta Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
SRPT Q2 2024 — $447.0M revenue
The results for the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year. Sarepta Therapeutics Inc reported Q2 2024 results. Net income of $540.7M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $447.0M.
- Net income: $540.7M.
- Operating income: $701.
Headline financials
Revenue & EPS history
Sarepta · Revenue · Quarterly
$363M
Revenue by segment
Sarepta · $179M total across 2 segments · Q4 2023
- ELEVIDYS$147M—82.2%
- Collaboration and Other$31.7M+41.0%17.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-1.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+0.4%
Avg return
30 days after
46%
30 / 65 earnings
Positive
+23.3%
Q4 2022
Best reaction
-64.7%
Q3 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | -11.0% | -27.8% | |
| Q4 2025 | -8.0% | -16.3% | +5.3% | |
| Q3 2025 | -33.8% | -27.9% | -6.7% | |
| Q1 2025 | -21.2% | -22.2% | -8.0% | |
| Q4 2024 | -3.6% | -3.7% | -34.1% | |
| Q3 2024 | -3.7% | -5.7% | +2.5% | |
| Q2 2024 | -4.5% | -9.9% | -9.8% | |
| Q1 2024 | +3.1% | +6.6% | +2.5% | |
| Q4 2023 | -9.6% | -12.5% | -8.5% | |
| Q3 2023 | +15.5% | +19.0% | +25.4% | |
| Q2 2023 | -0.2% | -4.7% | +13.9% | |
| Q1 2023 | +0.3% | +4.7% | -0.7% | |
| Q4 2022 | +23.3% | +31.7% | +15.2% | |
| Q3 2022 | -8.0% | -12.0% | +10.7% | |
| Q2 2022 | +5.0% | +15.8% | +20.2% | |
| Q1 2022 | -2.2% | -11.1% | -0.5% | |
| Q4 2021 | +3.9% | +3.6% | +2.0% | |
| Q3 2021 | +6.7% | +9.4% | -3.7% | |
| Q2 2021 | +13.8% | +13.6% | +16.6% | |
| Q1 2021 | +0.8% | -5.4% | -1.4% | |
| Q4 2020 | +2.1% | -2.6% | -14.4% | |
| Q3 2020 | -17.3% | -15.5% | +4.1% | |
| Q2 2020 | -1.5% | +1.4% | -15.3% | |
| Q1 2020 | +3.5% | +13.7% | +23.9% | |
| Q4 2019 | -5.4% | +5.3% | -17.0% | |
| Q3 2019 | +4.3% | +8.3% | +18.6% | |
| Q2 2019 | -7.3% | -13.5% | -40.3% | |
| Q1 2019 | +2.4% | -3.4% | +6.6% | |
| Q4 2018 | +3.0% | +3.9% | -14.9% | |
| Q3 2018 | -6.6% | -13.0% | -11.1% | |
| Q2 2018 | +9.5% | +4.7% | +17.5% | |
| Q1 2018 | +14.5% | +9.2% | +22.2% | |
| Q4 2017 | +8.3% | +13.7% | +18.0% | |
| Q3 2017 | -2.7% | -2.1% | +15.6% | |
| Q2 2017 | +20.8% | +29.7% | +8.3% | |
| Q1 2017 | +4.0% | +2.9% | -13.9% | |
| Q4 2016 | -7.1% | +5.1% | -11.3% | |
| Q3 2016 | -8.2% | -10.0% | -16.3% | |
| Q2 2016 | +7.2% | +14.0% | +21.4% | |
| Q1 2016 | +2.8% | — | — | |
| Q4 2015 | -8.0% | — | — | |
| Q3 2015 | -0.8% | — | — | |
| Q2 2015 | -0.8% | — | — | |
| Q1 2015 | -0.3% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | +6.3% | — | — | |
| Q2 2014 | -3.3% | — | — | |
| Q1 2014 | -6.4% | — | — | |
| Q4 2013 | -1.4% | — | — | |
| Q3 2013 | -64.7% | — | — | |
| Q2 2013 | -5.2% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q4 2012 | -2.8% | — | — | |
| Q3 2012 | -6.8% | — | — | |
| Q2 2012 | -5.8% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q1 2012 | -27.9% | — | — | |
| Q4 2011 | +20.0% | — | — | |
| Q3 2011 | -5.7% | — | — | |
| Q2 2010 | +2.5% | — | — | |
| Q2 2011 | +2.5% | — | — | |
| Q4 2009 | +2.5% | — | — | |
| Q4 2010 | +2.5% | — | — | |
| Q3 2010 | -3.1% | — | — | |
| Q1 2010 | +11.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro